(Q36556729)

14 August 2017

1 reference

title

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation (English)

1 reference

post-transplant lymphoproliferative disorder

14 August 2017

main subject

0 references

Epstein–Barr virus

0 references

organ transplantation

1 reference

Wai H Lim

1

1 reference

14 August 2017

Graeme R Russ

series ordinal

2

1 reference

14 August 2017

Patrick T H Coates

series ordinal

3

1 reference

14 August 2017

publication date

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

355-366

1 reference

EBV persistence in memory B cells in vivo.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Identifying the patient at risk for post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

21 January 2018

The dual role of IL-10.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

B-cell-derived IL-10: production and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dominant expression of interleukin-10 and transforming growth factor-beta genes in activated T-cells of chronic active Epstein-Barr virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cells, tolerance induction and transplant outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Human peripheral blood contains two distinct lineages of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cell lineage, plasticity and cross-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: results of a prospective matched-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Adenovirus tubulointerstitial nephritis presenting as a renal allograft space occupying lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Lymphoproliferative disease after renal transplantation in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Successful renal retransplantation after post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Viruses and the type I interferon antiviral system: induction and evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Antiviral actions of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Rational approaches to human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Peripheral blood dendritic cells in human end-stage heart failure and the early post-transplant period: evidence for systemic Th1 immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

TLR9-Dependent Recognition of MCMV by IPC and DC Generates Coordinated Cytokine Responses that Activate Antiviral NK Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

Lymphomas occurring late after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2006.00596.X

10.1111/J.1440-1797.2006.00596.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference